Prostate Adenocarcinoma
Conditions
Keywords
Flibanserin, Androgen Deprivation Therapy (ADT)
Brief summary
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
Detailed description
More than 40,000 men with prostate cancer in the United States will begin androgen deprivation therapy (ADT) each year. ADT is an important part of treatment, because it improves survival for men with metastatic or high-risk localized disease, and reduces rates of biochemical progression for men with intermediate-risk localized disease who receive radiation. The most common ADT agents modulate gonadotropin-releasing hormone to suppress the downstream testosterone production, resulting in testosterone levels similar to those observed following surgical castration (\<20 ng/dL). Since male sexual interest is highly correlated with serum testosterone levels, loss of sexual interest is nearly universal among men who receive ADT.Sexual dysfunction is the most common complaint among men with prostate cancer and contributes to lower overall quality of life (QoL) experienced by men receiving ADT. Furthermore, the loss of sexual interest experienced during ADT is highly distressing for men with prostate cancer and their partners, which contributes additional psychological morbidity in these patients. Flibanserin is approved for treatment of female hypoactive sexual desire disorder, and the safety profile of 100mg daily flibanserin is well described in premenopausal women.The safety profile of flibanserin in healthy men has been assessed in multiple phase I clinical trials, but has not been evaluated among men receiving ADT for prostate cancer. This is a phase II randomized, double-blinded, placebo-controlled clinical trial designed to provide an initial estimate of the efficacy of flibanserin to promote sexual interest in men with prostate cancer receiving androgen suppression therapy and to confirm the safety profile. This study will take place at a single academic comprehensive cancer center. Following confirmation of eligibility, participants who are enrolled in this study are randomized to receive daily flibanserin 100mg or placebo for a 12-week period.
Interventions
DRUGFlibanserin 100 MG
Flibanserin 100mg tablets taken by mouth daily at bedtime
DRUGPlacebo
Visually identical placebo tablets taken by mouth daily at bedine
DRUGAndrogen deprivation therapy
Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Sponsors
Andrew McDonald
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Ability to take oral medication and be willing to adhere to the study regimen. * Male age \>18 years. * Histologically confirmed prostate cancer. * Currently receiving gonadotropin releasing hormone agonist/antagonist monotherapy. * Serum testosterone \<50 ng/dL. * Serum AST and ALT less than 2 times upper limit of normal. * Endorsed reduced sexual interest. * Attempted intercourse. * Current sexual partner. * Was sexually active with partner within 6 months prior to ADT. * No other antineoplastic therapy planned during study period. * No active symptoms attributable to systemic prostate cancer.
Exclusion criteria
* Current systemic prostate cancer treatment besides GnRH agonist/antagonist, anti-androgens, or abiraterone. * Prior to ADT had erections not firm enough for intercourse despite use of pharmacologic agents such as phosphodiesterase-5 inhibitors. * Current symptoms attributable to active prostate cancer * Moderate or heavy alcohol use (\>2 drinks/day) * Concurrent moderate or strong CYP3A4 inhibitors * Concurrently taking medication classified as a monoamine oxidase inhibitor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Reported Attempting Sexual Intercourse at Least 3 Times in the Prior Month | Baseline up to 12 weeks | The number of patients in each arm reporting attempting sexual intercourse at least 3 times in the prior month (0-2 attempts vs. 3+ attempts) will be compared using the two-group chi-square test, or Fisher's exact test if the assumptions for the chi-square test are not tenable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sexual Quality of Life (QoL) | 12 weeks | Determined using T-scores from the PROMIS v2.0 Brief Sexual Function and Satisfaction (Male) form and comparing T-score between patients receiving flibanserin and patients receiving placebo. Higher scores indicate better sexual functions. A T-score of 50 represents the population mean with a standard deviation of 10. The difference in 3 to 5 T-score points is generally considered a clinically meaningful change. |
| Frequency of Patient Reported Grade 3+ Adverse Events | Baseline up to 12 weeks | Toxicity will be assessed by a physician investigator and scored using the CTCAE v5.0 scale. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAndrew McDonald, MD
University of Alabama at Birmingham (UAB)
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 29 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants |
| Age, Continuous | 67.6 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 21 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Region of Enrollment United States | 21 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 22 | 0 / 19 |
| other Total, other adverse events | 10 / 22 | 6 / 19 |
| serious Total, serious adverse events | 0 / 22 | 0 / 19 |
Outcome results
None listed